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Ⅰ. Abstract 
Objective. Cancers of breast, endometrium, and ovary have been regarded to be 
hormone-related. Several reproductive factors and obesity have been described as risk factors 
for these sites. However, similarities and differences in the risk factor profiles remain unclear. 
Further, the effect of exogenous hormone use on cancer risk is unclear in Japanese women. 
The objective of this hospital-based case-control study is to simultaneously evaluate 
associations of reproductive factors, exogenous hormone use, and body mass index (BMI) 
with the risk of breast, endometrial, and ovarian cancer. 
Methods. Study subjects consisted of 485 breast, 103 endometrial, 141 ovarian cancer 
cases and 2016 controls aged 30 and over admitted to a single hospital in Miyagi Prefecture 
from 1997 to 2003. Information on reproductive factors, other lifestyle factors, and current 
height and weight was collected using a self-administered questionnaire. For each site, odds 
ratios (ORs) and 95% confidence intervals (95% CIs) for exposure variables were estimated 
using an unconditional logistic regression analysis. The analysis was also conducted for a 
subgroup consisting of older aged subjects (aged 50 and over). 
Results. Associations of early age at menarche, nulliparity, and low parity with an 
increased risk of cancer were consistently observed for all sites. Associations with exogenous 
hormone use were observed for ovarian cancer (oral contraceptive, OR 0.41, 95% CI: 
0.13-1.34; other exogenous female hormones, OR 1.92, 95% CI: 1.01–3.63). Increasing BMI 
4 
 
was associated with an increased risk of older aged breast cancer (p for trend=0.02).  
Conclusions. The present study revealed similarities in reproductive risk factors and 
differences in the effects of exogenous hormone use and obesity among hormone-related 
female cancers. Reproductive factors are likely to equally contribute to the development of 
these cancers. To reduce the risk of hormone-related female cancers, the author should 
reconsider the role of childbirth in women’s health. 
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Ⅱ. Introduction 
Japanese women have a lower risk of breast, endometrial and ovarian cancer compared 
with women in Western countries1）. However, the incidence of these cancers in Japanese 
women has substantially increased over several decades 2）. During 1975–2000, the breast and 
ovarian cancer incidence rate doubled and endometrial cancer incidence rate increased 
threefold. Breast cancer has been the leading site in female cancer incidence since 1993. The 
age-adjusted breast cancer incidence rate to the world population was 36.7 in 2000. The 
aged-adjusted incidence rate of ovarian and endometrial cancer was 7.0 and 5.1 in 2000, 
respectively. Thus, the trend of female cancer incidence has become a serious public health 
concern in Japan3）. 
Cancers of breast, endometrium, and ovary have been regarded to be hormone-related, 
since these sites are target organs for sex hormones. Correlation studies among different 
countries have shown similar international distributions in the incidence of these cancers, 
which have suggested similarities in risk factor profile and the presence of common etiologic 
factors4-6）. Many epidemiologic studies have focused on associations of menstrual and 
reproductive factors and anthropometric measures with the risk of hormone-related female 
cancers8-13）. Among them, the risk factors for breast cancer have been extensively investigated. 
Previous studies in Western countries have consistently established the risk factors such as 
early age at menarche, late age at menopause, nulliparity, late age at first birth and obesity 
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(Table1) 7, 9, 11, 12）. Studies in Japan, albeit few in number, have produced findings on several 
reproductive and anthropometric risk factors , which are generally consistent with those in 
Western countries10, 13, 14）. However, there are some variations in the results among the studies 
in regard to cancers of endometrium and ovary (Table1) 8,12）. Thus, similarities in risk factor 
profiles among the hormone-related female cancers still remain unclear. In addition, there are 
few reports on the effect of exogenous hormones such as oral contraceptives (OC) in Japanese 
women 15,16）.  
To elucidate underlying etiologies of hormone related female cancers and to plan the 
prevention of the diseases, the author needs to identify risk factors including exogenous 
hormone use. Therefore, we carried out a hospital-based case-control study and 
simultaneously evaluated the associations of reproductive factors, exogenous hormone use, 
and obesity with the risk of breast, endometrial and ovarian cancer. Since a common protocol 
is used for collecting data and for analysis, this study enables us to compare epidemiologic 
characteristics and to clarify similarities and differences in risk factor profiles among 
hormone-related female cancers.  
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Ⅲ.Material and Methods 
Study design and data collection procedure 
In January 1997, a questionnaire survey in connection with the present study was begun at 
Miyagi Cancer Center Hospital (MCCH). Information on lifestyle has been collected from all 
patients on their first admission to the MCCH, using a self-administered questionnaire. The 
questionnaire is distributed to patients on the day of reservation for first admission, i.e., 10-15 
days before admission, and collected on the day of actual admission by nurses. The MCCH is 
located in Natori City, situated in the southern part of Miyagi Prefecture, and functions as a 
hospital both for cancer and benign disease. Details of the questionnaire survey have already 
been described elsewhere 17). 
The questionnaire covers items on demographic characteristics including occupational 
history, general lifestyle before the development of current symptoms including personal and 
family histories of cancer and other disease, reproductive history, and exogenous hormone use, 
and current height and weight. Items related to the referral base (with and without referral, 
from screening, other) were also included. The reproductive history included age at menarche, 
history of pregnancy, age at first birth, parity number, and lactation. Regarding exogenous 
hormone use, patients were simply asked whether they had previously used OC and other 
exogenous female hormones. Between January 1997 and December 2003, the questionnaire 
was given to 12,929 first admitted patients and 11,682 responded (response rate 90.4%). This 
study was approved by the review board of Miyagi Cancer Center. 
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Study subjects 
Cases and controls were consecutively selected from women aged 30 and over who 
responded to the above questionnaire survey. To identify incident cases of cancer, a list of the 
patients was linked with the hospital-based cancer registry files. The registry records all 
cancer cases confirmed by clinical, cytological and/or histopathological examination at the 
MCCH. Their personal history on the questionnaire and medical records were also checked, 
and cancer patients with past history of cancer were excluded from the incidence cases. 
Consequently, 485 breast, 103 endometrial and 141 ovarian cancer cases were identified. 
Three patients diagnosed as having incident cancers of ovary and endometrium were taken as 
case for each site. 
Controls were selected from non-cancer patients aged 30 and over without a past history 
of cancer. Patients with benign tumors have been classified as non-cancer patients in the 
present study. Accordingly, 2016 non-cancer patients were identified as controls. The 
diagnoses among controls were as follows: benign tumor 1112 (55.2%), cardiovascular 
disease 110 (5.5%), digestive tract disease 288 (14.3%), respiratory tract disease 93 (4.6%), 
urologic-gynecologic disease 131 (6.5%), other benign disease 161 (8.0%), and no abnormal 
findings 121 (6.0%).  The sites of benign tumors were digestive tract 393, gynecologic organ 
321, urologic organ 15, breast 15, bone or connective tissue 272, and other 96.  
The response rate for each cancer site was 92.6% for breast, 88.8% for endometrium, and 
94.6% for ovary, and that for control group was 90.5%. 
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Statistical analysis 
Prior to the statistical analysis, we investigated distributions of age, area of residence, 
and referral base among cases and controls. The distributions of other covariates such as 
smoking were also investigated. Body mass index (BMI), i.e., obesity indicator was 
calculated based on self-reported current height and weight described in the questionnaires. 
However, since some missing or incomplete data were found in the self-reported height and 
weight data, we compensated with measured height and weight data retrieved from the 
clinical database at the MCCH. Consequently, 169 measured height data and 183 measured 
weight data were retrieved for the analysis. The correlation coefficient between self-reported 
and measured height in a subsample in the present study was 0.94, and that between 
self-reported and measured weight was 0.92.   
For each site, odds ratios (ORs) and 95% confidence intervals (95% CIs) for each 
reproductive factor, exogenous hormone use, and body mass index were estimated with 
adjustment for age, year of survey, occupation, and known risk factors of cancer such as 
smoking history, history of alcohol drinking, and family history of index cancer in parents and 
siblings, using an unconditional logistic regression model 16). If necessary, some other 
covariates were also entered into the model. Subjects with missing values for smoking history 
and history of alcohol drinking were considered to be never-users. The cut-off points for 
reproductive factors were arbitrarily determined, based on the distributions in control 
subjects: age at menarche and age at first birth were categorized into 3 groups (age at 
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menarche ≤12, 13-14, ≥15; age at first birth ≤23, 24-28, ≥29) and parity number was 
categorized into 4 groups (nulliparous; parity number 0, 1, 2, ≥3), respectively. Lactation was 
categorized into 3 groups (bottle milk only, bottle milk and breast-feeding, and breast-feeding 
only). Body mass index was categorized into 4 groups (<21, 21≤ <23, 23≤ <26, 26≤) based on 
quintile points in control subjects.  
Analyses were conducted for all subjects (≥30 y.o., n=2,745) and for a subgroup 
consisting of older aged subjects (≥50 y.o., n=1,950), respectively. The mean age at 
menopause among all subjects was 49.9 years. Among older aged subjects, 144 subjects 
(7.4%) were premenopausal and 1,182 subjects (60.6%) were natural menopausal, although 
the ages at menopause among 328 subjects (16.8%) were unknown because of surgical 
menopause or other reasons. For the 296 older aged subjects (15.2%), data on menopausal 
status were missing. Thus, it is likely that most of the subjects aged 50 and over are regarded 
to be postmenopausal. 
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Ⅳ. Results 
Table 2 shows distributions of background characteristics in study subjects. Endometrial 
cancer cases were older than breast and ovarian cancer cases. Slight differences in the 
distribution of area of residence were observed between cases and controls. There were 
variations in referral patterns between cases and controls. About 14% of cases with breast 
cancer were derived from screening. Many subjects with cancers of endometriem and ovary 
were admitted with referral. About 20% of controls had visited the hospital without referral. 
Some differences in occupational history were also observed between cases and controls. In 
endometrial cancer cases, for example, the frequency of professional workers was 9.7%. The 
frequency of smoking history was 19.2% in ovarian cancer cases. In breast and ovarian cancer, 
the frequency of cases with a family history of index cancer was higher than that of controls. 
Table 3 shows ORs and 95% CIs of reproductive factors and exogenous hormone use for 
each cancer site among all aged subjects. The ORs were adjusted for age, year of survey, and 
confounding variables, some of which were selected based on the characteristics among the 
study subjects shown in Table 2. Subjects with missing values on exposure variables were 
excluded from the analyses. Increasing age at menarche was significantly associated with a 
decreased risk of ovarian cancer (p for trend=0.002). A similar trend was also found for 
endometrial cancer (p for trend=0.09). A significantly increased OR for nulliparity was 
observed for endometrial and ovarian cancer (endometrium, OR 3.62: 95% CI 2.04–6.40; 
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ovary, OR 2.36: 95% CI 1.40–3.98). Late age at first birth (aged 29 and over) was 
significantly associated with an increased risk of breast cancer (OR 1.73: 95% CI 1.23–2.43). 
A significant association of increasing parity number with a decreased risk of cancer was 
consistently observed for all sites. Its association was much clear in cancers of endometrium 
and ovary. The analysis on exogenous hormone use revealed that the use of OC was inversely 
associated with ovarian cancer risk, although statistical testing showed non-significance. The 
use of other exogenous female hormones was significantly associated with an increased risk 
of ovarian cancer (OR1.92, 95% CI: 1.01–3.63).  
The ORs among older aged subjects (≥50 y.o.) are presented in Table 4. Some 
differences in the magnitude of OR were found between all aged and older aged subjects. 
Although the association of age at menarche with breast cancer risk was insignificant in the 
analyses for all aged subjects, its association turned out to be significant in older aged subjects. 
The associations of parity number and age at first birth with breast cancer risk also turned out 
to be clearer in older aged subjects. For ovarian cancer, the associations with age at first birth 
and exogenous female hormone use turned out to be clearer in older aged subjects.  
Table 5 and 6 show ORs and 95% CIs of BMI for each cancer site. Among all aged 
subjects, an increased OR for high BMI category (≥26 kg / m2) was observed for breast and 
endometrial cancer, but the corresponding linear trend was not significant. In older aged 
subjects (≥50 y.o.), a linear relationship between BMI and OR was found for breast cancer (p 
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for trend=0.02). A significantly increased OR for the high BMI category was also observed 
(OR 1.52, 95% CI: 1.03–2.24). 
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Ⅴ. Discussion 
In the present study, we evaluated the associations of reproductive factors, exogenous 
hormone use, and obesity with the risk of hormone-related female cancers, i.e. breast, 
endometrial and ovarian cancer, using a common protocol. Epidemiologic studies have 
clarified several risk factors for the hormone-related female cancers in Japanese women 10, 12, 
13, 15, 16, 19-23). Compared with these previous studies, ours is unique in simultaneously 
describing the risk factors and in evaluating the effect of exogenous hormone use. However, 
hospital-based case-control studies such as ours may suffer from some methodological 
problems. Before discussing the present findings, methodological problems merit 
consideration.  
First, we considered problems in selecting cases and controls. Theoretically, eligibility 
criteria for cases define the source population in case-control studies, from which controls 
should be selected. Namely, if hospitalized cancer cases are a biased sample of the general 
population, controls should also be a biased sample in the same way 24, 25）. In the present study, 
we selected controls from patients admitted to the same hospital as cases, although in some 
studies controls have been selected from patients visiting outpatient clinics or screening 
centers. Further, statistical analyses appropriately controlled background characteristics such 
as area of residence and referral patterns among study subjects. Thus, good comparability is 
kept between cases and controls. Second, in terms of methodology, it is possible that the 
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inclusion of benign tumors in the control group might have distorted the results, since patients 
with benign tumors may have a background similar to patients with cancers. To resolve this 
problem, we performed additional analyses as follows: patients with benign tumor in certain 
sites were excluded from controls for the site and ORs were reevaluated. Exclusion of benign 
tumors had no effect on the OR (data not shown in tables). Third, it is possible that 
information bias might have distorted the results. However, since the questionnaires were 
collected before any definite diagnosis or treatment at the MCCH, there would seem to be 
minimal recall bias. 
Among risk factors clarified in the present study, the associations of menstrual and 
reproductive risk factors with hormone-related female cancers have been investigated in 
previous epidemiologic studies. Especially, for breast cancer, a large number of studies have 
been conducted 7-12). The Japanese epidemiologic studies have shown consistent associations 
of early age at menarche, nulliparity, low parity, and late age at first birth with an increased 
risk of breast cancer10, 12, 19-21）. The present study also demonstrated similar associations. In 
older aged subjects, clearer associations with menstrual and reproductive risk factors were 
observed, which was consistent with the previous findings reported by our colleague19). In 
contrast to the abundant epidemiologic studies of breast cancer, studies of endometrial and 
ovarian cancer are few in Japan. The present study found similarities in reproductive risk 
factors between endometrial and ovarian cancer. Furthermore, these risk factors were 
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comparable to those for breast cancer mentioned above. In Japan, Hirose and Okamura have 
reported significant associations of parity history, parity number, and age at first birth with the 
risk of endometrial cancer16, 20）, and Mori et al. have reported the significant association of 
parity number with the risk of ovarian cancer15）. However, the significant association with age 
at menarche found in the present study has never been observed in these previous Japanese 
studies. The effect of age at menarche is unlikely to be established. Western studies have also 
shown no consistent association between age at menarche and the risk of endometrial and 
ovarian cancer9, 12).  
The present study failed to demonstrate a significant effect of breast-feeding, although 
breast-feeding has been considered a possible important risk factor for breast and endometrial 
cancer16, 26, 27）. To elucidate the effect of breast-feeding, detailed information such as duration 
of lactation may be required. 
We also focused on the effect of exogenous hormone use. In Western countries, exogenous 
hormones including OC and hormone replacement therapy (HRT) have been widely used over 
the past decades29）. Numerous studies have evaluated the association of the use of these 
exogenous hormones with the risk of hormone-related female cancers9, 28-34）. On the other 
hand, in Japan, the government did not allow low dose OC until 1998. The prevalence of 
exogenous hormone use has been low35, 36）. It remains unclear whether exogenous hormone 
use affects the risk of hormone-related female cancers in Japan. We supposed that Japanese 
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women have little knowledge of exogenous hormones. Therefore, data on only two surrogate 
items (OC use and use of other exogenous female hormones) were collected and analyzed in 
the present study, although it seems that high dose OC have been used in the source 
population of the present study. We found that the use of OC was inversely associated with 
the risk of ovarian cancer, although statistical testing showed non-significance. In Western 
studies, the inverse association with OC use has been consistently observed9, 12, 33）. It is 
hypothesized that protection of ovarian cancer by OC may be due to suppression of plasma 
pituitary gonadotropins or inhibition of ovulation9）. In Japan, only one report presented a 
similar result to ours 15）. In contrast to the effects of OC use, the use of other exogenous 
female hormones elevated ovarian cancer risk in the present study. Exogenous female 
hormones except for OC are mainly used for HRT and infertility therapy. Therefore, the 
present result may indicate the combined effects of both therapies. Although Western studies 
have reported that HRT and infertility therapy might be linked with an increased risk of 
ovarian cancer, respectively 34, 37, 38）, the effects of these therapies on ovarian cancer risk have 
been unknown in Japan. Our finding may thus provide important information for future 
studies. Regarding breast and endometrial cancer, a risk increase associated with exogenous 
hormone use such as HRT has been well known in Western countries28-30）. However, there is 
no evidence indicating such an association in Japanese women 12, 16, 39）. The present study also 
showed no association between exogenous hormone use and the risk of these two cancers.  
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In the analysis on obesity, we found an association of increasing BMI with an increased 
risk of older aged breast cancer. Japanese studies have shown the significant association of 
obesity with the risk of postmenopausal breast cancer 13, 22, 40）. The present finding was in line 
with these previous results. For endometrial cancer, similar associations with obesity were 
also observed, although statistically insignificant. This insignificant result may be due to the 
small sample size in endometrial cancer. Although associations of obesity with endometrial 
cancer risk have been few investigated in Japan 16, 23, 41）, obesity is regarded as an established 
risk factor for endometrial cancer in Western countries 42）. After menopause, i.e., in older aged 
women, direct ovarian estrogen production ceases and most estrogens are derived from the 
aromatization of adrenal androgens. Adipose tissue is rich in the aromatase enzyme, making it 
likely that estrogen production increases in obese women 43） . A higher risk of older aged 
breast and endometrial cancer associated with obesity may be explained by such hormonal 
environment in obese women. For ovarian cancer, an inverse association with increasing BMI 
was found. Several previous studies including one in Japan have shown an opposite finding to 
ours, i.e., positive association of obesity with the risk of ovarian cancer 15, 44, 45）. According to 
detailed data from the hospital-based cancer registry, ovarian cancers in the present study 
were more advanced (stage Ⅲand Ⅳ, 53.2%), compared with cancers of breast and 
endometrium (stage Ⅲand Ⅳ, breast 20.0%; endometrium 30.1%). The ovarian cancer cases 
might have suffered from weight loss due to sickness. However, the possibility that the effect 
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of obesity may differ between ovarian cancer and other two sites cannot be ruled out.   
The present study revealed similarities in associations with reproductive factors and 
differences in associations with exogenous hormone use and obesity among cancers of breast, 
endometrium, and ovary. The similarities were pronounced in older aged subjects (≥50 yrs). 
These findings suggest that hormone-related female cancers, especially older aged cancers, 
may have similar etiologies to some extent. Reproductive factors are likely to equally 
contribute to the development of these cancers, although exogenous hormone use and obesity 
may have different effects. Using the ORs among all aged subjects shown in Table 3, we 
attempted to calculate the population attributable risk (PAR) for the reproductive history 
combining 29 y.o. over at first birth and nulliparity 46）. In terms of the PAR, a certain 
proportion of hormone-related female cancers were related to such reproductive history: 8.0% 
of breast cancers, 11.7% of endometrial cancers, and 14.7% of ovarian cancers. 
In recent decades, lifestyles in Japanese women have been greatly changed. Frequency of 
nulliparity has been increasing and the mean age at first birth has been elevated 47）. The PAR 
level suggests that the trend in reproductive histories would be related to the increased 
incidence of hormone-related female cancers. From the viewpoint of cancer prevention, 
reproductive risk factors have been regarded as unavoidable, although exogenous hormone 
use and obesity are avoidable risk factors. However, to reduce the risk of hormone-related 
female cancers, we must better understand the reproductive risk factors and reconsider the 
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role of childbirth in women’s health.
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Ⅵ. Conclusions. 
The present study revealed similarities in reproductive risk factors and differences in the 
effects of exogenous hormone use and obesity among hormone-related female cancers. 
Reproductive factors are likely to equally contribute to the development of these cancers. To 
reduce the risk of hormone-related female cancers, the author should reconsider the role of 
childbirth in women’s health. 
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Ⅸ. Tables 
Table1.Epidemiology of breast, endometrial and ovarian cancer: risk factor identified in previous studies* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Breast Cancer Endometrial Cancer Ovarian Cancer  
Western Japan Western Japan Western Japan 
Early menarche ↑↑ ↑↑ ↑ － － － 
Menopause ↑  ↑  －  
Nulliparity ↑↑ ↑↑ ↑↑ － ↑↑  
Multiple parity ↓ ↓ ↓ ↓ ↓ ↓ 
Age at first birth>30y  ↑↑ ↑↑ － －   
Family history ↑↑ － － － ↑↑  
Lactation ↓ － － ↓ ↓ ↓ 
Obesity (postmenopausal) ↑ ↑ ↑↑ ↑ － － 
(premenopausal) ↓ ↓     
HRT1) use ↑↑ ↑ － － － － 
Oral contraceptive use ↑  ↓↓ － ↓↓ － 
Tamoxifen ↓  ↑    
Arrows indicate the approximate magnitude of the relationship: ↑, slight to moderate increase in risk; ↑↑, moderate to large 
increase in risk; ↓, slight to moderate decrease in risk; ↓↓, moderate to large decrease in risk; －, inconsistently 
1)HRT, Hormone replacement therapy  
*Adami HO,2002; Kelsey JL,1993; Kelsey JL,1994; Persson I,2000; Hanter DJ,1993; Nagata C,1995; Mori M,1998; 
Okamura C,2006;Hirose K,1999; Minami Y,1997; Tamokoshi K,2005; Iwasaki M,2007; Niwa K,2000; Inoue M,1994 
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Table 2 Distribution of characteristics in cases and controls 
Controls Breast Endometrium Ovary 
Category 
n=2016 n=485 n=103 n=141 
Age group (years old)     
 30-39 170 24 3 13
 40-49 409 131 13 32
 50-59  429 141 42 44
 60-69 515 105 24 30
 70≤ 493 84 21 22
Average age ±SD 58.7±13.6 56.7±12.2 59.4±10.5 55.6±12.8
Area of residence (%)     
  Southern Miyagi Pref. 90.6 86.2 83.5  85.8 
  Other 9.4 13.8 16.5  14.2 
Referral base (%)     
  Without referral 19.4 35.1 10.7  12.8 
  With referral 56.5 41.7 80.6  79.4 
  From screening 16.4 14.4 2.9  1.4 
  Other 7.7 9.0 0.8  6.4 
Occupation (%)     
  Professional 6.4 7.8 9.7  3.6 
  Clerical 16.2 17.3 18.5  17.0 
  Agricultural 10.9 7.0 7.8  7.8 
  Industrial 13.4 19.0 16.5  10.6 
  Other 53.1 48.9 47.6  61.0 
 Smoking (%)    
  Yes 15.6 16.3 9.7  19.2 
  No 80.8 83.5 84.5  75.9 
  Unknown 3.6 0.2 5.8  5.0 
Alcohol drinking (%)   
 Yes 23.0 24.1 20.4  20.6 
 No 71.5 71.1 73.8  73.1 
 Unknown 5.5 4.7 5.8  6.4 
Family history of breast cancer (%)   
  Absent 95.8 91.3  
  Present 4.2 8.7  
Family history of uterus cancer (%)1)     
  Absent 96.8 97.1  
  Present 3.2 2.9  
Family history of ovarian cancer (%)     
  Absent 99.6  98.6 
  Present 0.4  1.4 
1) Uterus cancer includes cancers of all parts in uterus.   
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Table 3 Odds ratios (ORs) and 95% confidence intervals (95% CI) of reproductive variables for breast, endometrial and 
ovarian cancer (Miyagi Prefecture, Japan, 1997-2003, ≥30 y.o.) 
Controls Breast Endometrium  Ovary 
(n=485) (n=103)  (n=141) 
Variable 
(n=2016)
No. of 
cases 
OR 95% CI No. of 
cases
OR 95% CI  No. of 
cases 
OR 95% CI 
Age at menarche (years)1)          
  ≤12 412 113 1.00 25 1.00   43 1.00 
  13-14 732 219 1.17 0.89-1.54 41 0.86 0.50-1.48  57 0.76 0.49-1.19
  ≥15 693 137 0.79 0.57-1.11 32 0.59 0.31-1.12  30 0.39 0.22-0.71
  Trend  p=0.14 p=0.09    p=0.002
Parity history1)      
  Yes 1758 429 1.00 80 1.00   113 1.00 
  No 132 39 1.15 0.78-1.69 19 3.62 2.04-6.40  22 2.36 1.40-3.98
Age at first birth (years)1) 4) 
 
 
 
    
  ≤23 593 124 1.00 21 1.00   34 1.00 
  24-28 881 217 1.12 0.87-1.44 47 1.55 0.90-2.65  55 1.13 0.72-1.78
  ≥29 202 75 1.73 1.23-2.43 6 0.95 0.37-2.41  18 1.58 0.86-2.93
  Trend  p=0.0044 p=0.5234    p=0.1785
Parity number1)      
  0 132 39 1.00 19 1.00   22 1.00 
  1 170 52 1.01 0.62-1.65 6 0.24 0.09-0.64  17 0.62 0.31-1.24
  2  777 213 0.95 0.63-1.41 40 0.31 0.17-0.57  52 0.42 0.24-0.73
  ≥3  726 144 0.72 0.47-1.09 29 0.21 0.11-0.42  38 0.33 0.18-0.60
  Trend  p=0.03 p=0.0001    p=0.0002
Breast-feeding2) 4)     
  Bottle milk only 281 70 1.00 14 1.00   25 1.00 
  Bottle milk and 
breast-feeding 
810 239 1.22 0.89-1.68 37 1.02 0.52-2.02  52 0.80 0.47-1.36
  Breast-feeding only 619 114 0.79 0.55-1.15 26 0.73 0.34-1.58  31 0.68 0.37-1.25
  Trend  p=0.11 p=0.34    p=0.22
Oral contraceptive use3)      
  No 1649 428 1.00 85 1.00   126 1.00 
  Yes 97 29 1.04 0.66-1.63 5 1.30 0.50-3.42  3 0.41 0.13-1.34
Use of exogenous female 
hormones except for oral 
contraceptive 3) 
     
  No 1636 423 1.00 82 1.00   113 1.00 
  Yes 85 22 0.88 0.54-1.44 6 1.15 0.47-2.81  13 1.92 1.01-3.63
1) OR was adjusted for age, year of survey, referral base (from screening, others), area of residence, BMI, smoking history, history of alcohol drinking, family 
history of index cancer in parents and siblings, and occupation (professional or clerical work, other work). 
2) OR was adjusted for age, year of survey, referral base (from screening, others), area of residence, BMI, smoking history, history of alcohol drinking, family 
history of index cancer in parents and siblings, occupation (professional or clerical work, other work), and parity number. 
3) OR was adjusted for age, year of survey, referral base (from screening, others), area of residence, smoking history, history of alcohol drinking, family history 
of index cancer in parents and siblings, occupation (professional or clerical work, other work), and parity history. 
4) Analyses were performed for parous women. 
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Table 4 Odds ratios (ORs) and 95% confidence intervals (95% CI) of reproductive variables for breast, endometrial 
and ovarian cancer (Miyagi Prefecture, Japan, 1997-2003, ≥50 y.o.) 
Controls Breast Endometrium  Ovary 
(n=330) (n=87)  (n=96) 
Variable 
(n=1437) 
No. of 
cases 
ORs 95% CI  
No. of 
cases 
ORs 95% CI   
No. of 
cases 
ORs 95% CI 
Age at menarche (years)1)       
≤12 144 52 1.00 18 1.00   19 1.00 
13-14 482 144 0.90 0.61-1.32 35 0.86 0.50-1.48  39 0.70 0.38-1.27
≥15 643 121 0.66 0.44-1.00 30 0.59 0.31-1.12  29 0.44 0.22-0.87
Trend   p=0.02 p=0.07    p=0.02
Parity history1)  
 
 3
126 46 41-3.34 6 0.47-3.2 13 02-4.37
p=0.0009 p=0.3660 p=0.07
ity number1)   
1
562 10 25-0.75 27 0.11-0.4 30 14-0.69
p=0.0003 p=0.0001 p=0.001
   
  Bo
14
feeding only 544 9 0.57-1.40 23 0.34-1.58 24 0.31-1.31
p=0.38  p=0.34  p=0.22  
ntraceptive use3)   
11 7
37 15 1.33 0.70-2.53 4 1.30 0.50-3.42  1 0.33 0.04-2.47
U
raceptive 3)  
     
11 7
 
1 nce, BMI, smoking history, history of alcohol drinking, family history of index 
2 oking history, history of alcohol drinking, family history of index 
3 g history, history of alcohol drinking, family history of index 
fessional or clerical work, other work), and parity history. 
4) Analyses were performed for parous women.     
     
 Yes 1272 295 1.00 70 1.00   82 1.00 
 No 53 23 2.00 1.18-3.39 14 4.76 2.41-9.43  10 2.73 1.29-5.79
Age at first birth (years)1)4) 
     
  ≤23 456 83 1.00 19 1.00   24 1.00 
  24-28 620 154 1.28 0.94-1.74 9 1.44 0.81-2.57  40 1.20 0.70-2.07
  ≥29 2.17 1. 1.23 0  2.11 1.
Trend      
Par     
0 53 23 1.00 4 1.00   10 1.00 
1 91 35 0.86 0.45-1.66 6 0.24 0.09-0.64  13 0.86 0.34-2.16
2 550 138 0.50 0.29-0.87 33 0.31 0.17-0.57  34 0.31 0.14-0.69
≥3 6 0.43 0. 0.21 2   0.31 0.
Trend      
Breast-feeding 2) 4)    
  Bottle milk only 
ttle milk and  
185 47 1.00 11 1.00   19 1.00 
breast-feeding 
502 7 1.25 0.84-1.86 33 1.02 0.52-2.02  34 0.72 0.38-1.34
  Breast- 8 0.90 0.73   0.63 
 Trend     
Oral co    
  No 56 292 1.00 4 1.00   87 1.00 
  Yes 
se of exogenous female 
hormones except for 
oral cont
  No 36 287 1.00 0 1.00   78 1.00 
 Yes 42 12 0.92 0.47-1.80  4 1.15 0.47-2.81   9 2.99 1.36-6.56
) OR was adjusted for age, year of survey, referral base (from screening, others), area of reside
cancer in parents and siblings, and occupation (professional or clerical work, other work). 
) OR was adjusted for age, year of survey, referral base (from screening, others), area of residence, BMI, sm
cancer in parents and siblings, occupation (professional or clerical work, other work), and parity number. 
) OR was adjusted for age, year of survey, referral base (from screening, others), area of residence, smokin
cancer in parents and siblings, occupation (pro
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Table 5 Odds ratios (ORs)1) and 95% confidence intervals (95% C
agi Pref n, 19
Controls Breast  Ovary 
(n=485) (n=103)  (n=141) 
Variable 
(n=2016) 
cases 
ORs 95% CI 
cases 
ORs 95% CI  
cases 
ORs 95% CI
No. of No. of No. of 
Body mass index            
       <21 487 110 1.00  20 1.00   44 1.00  
  21≤  <23 433 103 1.09 0.80-1.48 23 1.37 0.72-2.60  36 0.93 0.58-1.50
  23≤  <26 
457 118 1.24 0.91-1.68 30 086-3.10 25 8-1.11
1)
 family history of index cancer in parents and siblings, occupation (professional or clerical work, other work), and parity 
history. 
596 144 1.20 0.89-1.60 30 1.28 0.68-2.39  34 0.70 0.43-1.15
  26≤ 1.64  0.65 0.3
    Trend     p=0.14    p=0.18   p=0.06   
 OR was adjusted for age, year of survey, referral base (from screening, others), area of residence, smoking history, history of alcohol 
drinking,
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Table 6 Odds ratios (ORs)1) and 95% confidence intervals (95% CI) o
an canc refect 03, ≥50 y.o.）
Controls Breast dometriu  Ovary 
(n=1437) (n=330) (n=87)  (n=96) 
Variable 
  
cases 
ORs 95% CI
cases 
ORs 95% CI  
cases 
ORs 95% CI
No. of No. of No. of 
Body mass index            
       <21 300 57 1.00  13 1.00   27 1.00  
  21≤  <23 291 62 1.13 0.75-1.71 22 1.77 0.83-3.76  25 0.96 0.53-1.74
  23≤  <26 
357 100 3-2.24 27 0.94-4.24 18 2-1.17
1)
drinking, family history of index cancer in parents and siblings, occupation (professional or clerical work, other work), and parity history. 
448 103 1.29 0.88-1.88 25 1.50 0.71-3.16  24 0.61 0.33-1.12
  26≤ 1.52 1.0 1.99  0.61 0.3
   Trend     p=0.02      p=0.13   p=0.06   
 OR was adjusted for age, year of survey, referral base (from screening, others), area of residence, smoking history, history of alcohol 
 
 
